Quick Answer
Acurx Pharmaceuticals, Inc. reported Net Income Loss of -$7.97 million for the year ending 2025.
- Acurx Pharmaceuticals, Inc. showed an increase of +43.5% in Net Income Loss from 2024 to 2025.
- This data is from Acurx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.28 million | Q2 2020: -$913.4 thousand | Q3 2020: -$1.31 million | Q1 2021: -$1.47 million | Q2 2021: -$4.00 million | Q3 2021: -$4.64 million | Q1 2022: -$2.67 million | Q2 2022: -$2.62 million | Q3 2022: -$3.54 million | Q1 2023: -$2.90 million | Q2 2023: -$3.45 million | Q3 2023: -$3.11 million | Q1 2024: -$4.38 million | Q2 2024: -$4.12 million | Q3 2024: -$2.82 million | Q1 2025: -$2.15 million | Q2 2025: -$2.25 million | Q3 2025: -$1.99 million.
- Over the full 6 years of available data (2020 to 2025), Acurx Pharmaceuticals, Inc.'s Net Income Loss has declined by 73.2%.
- Historical annual values: Fiscal year 2025: -$7.97 million | Fiscal year 2024: -$14.10 million | Fiscal year 2023: -$14.58 million | Fiscal year 2022: -$12.09 million | Fiscal year 2021: -$12.75 million | Fiscal year 2020: -$4.60 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: